US FDA advisors say 'no' to Sanofi's semuloparin for VTE prevention in cancer patients
04:20 EDT 21 Jun 2012 | SCRIP
Hopes for approval by the US FDA of a new blood thinning drug developed by Sanofi-Aventis dimmed considerably 20 June, when the agency's Oncologic Drug Advisory Committee (ODAC) of outside experts took an unequivocal stance against.....
Original Article: US FDA advisors say 'no' to Sanofi's semuloparin for VTE prevention in cancer patients
More From BioPortfolio on "US FDA advisors say 'no' to Sanofi's semuloparin for VTE prevention in cancer patients"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
